ABSTRACT: Introduction: Comprehensive genetic testing for dystrophinopathy can detect 95% of pathogenic variants in the dystrophin gene (DMD) and is often the preferred diagnostic approach. Methods: We reviewed pathology reports for muscle biopsies evaluated at the University of Iowa with a pathological diagnosis of dystrophinopathy based on dystrophic histopathology and abnormal immunofluorescence staining: reduced to absent dystrophin, expression of utrophin, and loss of neuronal nitric oxide synthase. Results: The percentage of muscle biopsies with dystrophinopathy has been stable since 1997. Among 2,298 biopsies evaluated between 2011 and 2016, 72 (3.1%) had pathologic features of dystrophinopathy. Median age at biopsy was 8 years (range, 0.66-84). Half had undergone DMD genetic testing prior to biopsy. Clinical phenotypes recorded on requisitions were typical of muscular dystrophy for 57 (79%) biopsies. Discussion: Muscle biopsy continues to play an important role in the diagnosis of dystrophinopathy, particularly in patients with later symptom onset, comorbidities, or normal DMD genetic testing results. 58: 148-152, 2018 Dystrophinopathy (Duchenne-Becker muscular dystrophy) is an X-linked recessive disorder with a prevalence of 1.38 per 10,000 men aged 5-24 years in the United States.
Dystrophinopathy (Duchenne-Becker muscular dystrophy) is an X-linked recessive disorder with a prevalence of 1.38 per 10,000 men aged 5-24 years in the United States. 1 Patients with Duchenne muscular dystrophy (DMD) typically present between the ages of 1.2 and 8 years with muscle weakness and delayed motor development. 2 In contrast, the mean age of onset in Becker muscular dystrophy (BMD) is 12 years, and patients with BMD have slower progression. 3 The preferred diagnostic approach to a patient with probable dystrophinopathy is genetic testing followed by muscle biopsy if results of genetic testing are normal. 4 Deletion/duplication testing and sequencing of the dystrophin gene (DMD) can detect 95%-98% of pathogenic DMD variants. 5, 6 The University of Iowa Hospitals and Clinics (UIHC) is a referral center for muscle biopsy evaluation. We evaluated how the role of muscle biopsy in dystrophinopathy has changed with the improvements in and availability of genetic testing.
MATERIALS AND METHODS
This study was approved by the University of Iowa Institutional Review Board. The total number of muscle biopsies (male and female) evaluated at UIHC and the number of biopsies diagnosed with dystrophinopathy was determined by searching the past 20 years of anatomic pathology cases in the laboratory information system. Complete pathology reports issued for dystrophinopathy cases between 2011 and 2016 were reviewed to verify that there was dystrophic histopathology and an abnormal pattern of immunofluorescence staining characteristic of a dystrophinopathy: reduced to absent dystrophin, expression of utrophin, and loss of neuronal nitric oxide synthase (nNOS). Prior to 2005, the antidystrophin (NCL-DYS1, NCL-DYS2, and NCL-DYS3) mouse monoclonal antibodies were from Novocastra/Leica Biosystems (Nussloch, Germany). Beginning about 2005, the expression of dystrophin was initially evaluated with 4 antibodies: the rabbit polyclonal anti-C-terminus antibody ab15277 (Abcam, Cambridge, MA) and mouse monoclonal antidystrophin antibodies (Developmental Studies Hybridoma Bank [DSHB], University of Iowa, Iowa City, IA), directed at the rod domain exon 50 (MANEX50), rod domain exon 46 (MANEX46B), and amino terminus exons 7/8 (MAN-EX7B). Additional antidystrophin antibodies directed at exons 1, 8, 10-12, 20/21, 27, 31/32, 38/39, 43, 45, 47, 48, and 48-50 (all from DSHB) were used as required to better characterize dystrophin expression. Antiutrophin (NCL-DRP2) and antinNOS (NCL-NOS1) antibodies were purchased from Novocastra/Leica Biosystems. Data were abstracted from these reports, including the indication(s) for biopsy, referring physician, clinical information, and genetic testing results. For each of the past 20 years, we determined the percentage of total biopsies with a pathological diagnosis of a dystrophinopathy together with 95% confidence intervals.
We grouped biopsies on the basis of whether DMD genetic testing was performed prior to biopsy and subdivided groups by clinical information abstracted from the reports. Typical DMD presentation was classified as age at biopsy (presumed to be near the time of presentation to a neurologist) between 1.2 and 8 years 2 with weakness, delayed motor development, elevated creatine kinase, and/or hypertrophic calves. 2, 3 We attempted to supplement the biopsy reportderived information by contacting referring physicians by mail. Among the 55 requests for information, 3 responded. Their responses are included in our results.
RESULTS
Twenty-Year Trend. UIHC evaluated 5,999 muscle biopsies (56% male) from 1997 to 2016, and 247 (4.1%) of those were diagnosed with dystrophinopathy by muscle pathology and immunofluorescence. The absolute number of muscle biopsies diagnosed annually with dystrophinopathy has been relatively stable (Fig. 1A) , and the annual percentage of dystrophinopathy biopsies has generally been between 2% and 5%. Confidence intervals overlap, with the exception of the year 2000 (12.1%; Fig. 1B ).
2011-2016 Cohort. Among 2,298 muscle biopsies evaluated at UIHC from 2011 to 2016, 72 (3.1%) had pathologic features of dystrophinopathy. Among these, half had DMD genetic testing prior to biopsy. Four biopsied patients had non-DMD genetic testing prior to biopsy (CAPN3 sequencing, LAMA2 sequencing, myotonic dystrophy panel, and limb-girdle muscular dystrophy [ LGMD] panel without including DMD). Eleven biopsied patients had normal DMD genetic testing results prior to biopsy. In 25 patients, a DMD variant was identified prior to biopsy (see Fig. 2A ).
Clinical information was available in 70 (97%) dystrophinopathy pathology reports from 2011 to 2016. Fifty-seven (79%) had a clinical phenotype reported that suggested dystrophinopathy. Among these, 32 reports had a DMD phenotype; 22 (69%) had DMD genetic testing prior to biopsy. The other 25 reports described a later onset presentation of typical muscular dystrophy; 12 (48%) had DMD genetic testing prior to biopsy. The median age of biopsy was 8 years (range, 8 months-84 years), and 16 (22%) biopsies were performed when the patient was older than 18 years (Fig. 2B) . Clinical features that are not typical of dystrophinopathy based on sex or comorbid conditions were reported for 13 biopsied patients, (Table 1) . Neuropathy was the most common comorbid condition in this series.
DMD genetic testing results were received after the biopsy for 8 patients: 3 were pathological DMD variants, 1 was a DMD variant of unknown significance (see Supp. Info. Table 1) , and DMD intronic variants were identified by RNA analysis for the remaining 4.
Referring health professionals named on requisitions were predominantly neurologists and pathologists. With rare exceptions, referral biopsies did not have immunohistochemistry performed locally; biopsies were sent to UIHC for this testing.
DISCUSSION
Our results show that muscle biopsy continues to be a part of patient diagnosis and care for a subset of individuals with dystrophinopathy. The annual absolute number and percentage of muscle biopsies evaluated at the University of Iowa with a pathological diagnosis of dystrophinopathy has not changed substantially over the past 20 years, despite the advances in genetic testing. From 2011 to 2016, more than two-thirds of the biopsy reports suggesting a typical DMD presentation also reported DMD testing prior to biopsy. However, less than half of those reporting a later onset of typical muscular dystrophy had DMD testing prior to biopsy, suggesting dystrophinopathy was not the suspected diagnosis. This is consistent with the broader range of diagnostic possibilities outside of early childhood. 7 Nearly 25% of patients with a dystrophinopathy pathologic diagnosis were older than 18 years when their biopsy was performed. Dystrophin abnormalities have previously been reported in 17% of all patients and 31% of male patients with an LGMD presentation. 8 The clinical findings in these older individuals often do not allow distinction between BMD and LGMD, particularly if there is no known family history of muscular dystrophy. According to the LGMD practice parameter, muscle biopsy is the preferred diagnostic approach in this population. 7 However, with the increasing availability of Table 1 .
next-generation sequencing panels, this diagnostic approach might be in evolution.
Muscle biopsy was sometimes requested to provide prognostic information or to understand the phenotype by quantifying dystrophin in muscle. For example, a referral biopsy case had an out-of-frame DMD deletion and was expected to have a DMD phenotype, 9-11 but his clinical progression was slower than expected. Biopsy was performed to reconcile these findings. As genotype-phenotype relationships and the role of modifier genes are better defined, 6 ,12-14 we predict that fewer dystrophinopathy biopsies will be ordered for prognostic information.
Finally, 2%-5% of individuals with dystrophinopathy have DMD mutations that cannot be detected by deletion/duplication analysis or sequencing. 5, 6 Eleven (15%) biopsies in our series had normal DMD testing results prior to muscle biopsy, and 5 patients had a variant of unknown significance in DMD prior to biopsy. Muscle biopsies are still required for the diagnosis of dystrophinopathy in these patients, both to determine dystrophin expression and to allow research-based analysis of RNA for identification of mutations in noncoding regions. Establishing a genetic diagnosis for patients with dystrophinopathy remains important for genetic counseling and disease management, particularly in the era of emerging genetic therapies for dystrophinopathy. 6, 9 Some patients with typical presentation of DMD had a muscle biopsy prior to any genetic testing. We hypothesize that barriers to genetic testing, such as cost or insurance restrictions on genetic testing, might explain some of these biopsies. In others, physicians might simply prefer to do the biopsy to guide genetic testing, particularly if the clinician is less comfortable with ordering and interpreting genetic tests.
Limitations of our study include sparse clinical history and lack of a detailed rationale for performing the biopsy available for some muscle biopsies. Biopsies are often referred by a pathologist, and requisitions are completed by the pathologist or support personnel. The brevity of clinical summaries may well be the result of this practice. We had little success in contacting the referring clinicians for additional information.
Although the preferred diagnostic approach to a patient with probable dystrophinopathy is genetic testing followed by muscle biopsy when genetic testing is normal, 4 the UIHC experience reported here indicates that muscle biopsies still play a role in diagnosis or management of dystrophinopathy. Muscle pathologists should use continuing vigilance for dystrophinopathy in their assessment of biopsies. Immunostaining for dystrophin in dystrophicappearing biopsies from male patients of any age will often pay diagnostic dividends. 
